Back to Search
Start Over
Abcuro to Presented Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells
- Source :
- Plus Company Updates. November 6, 2021
- Publication Year :
- 2021
-
Abstract
- NEWTON: Abcuro, Inc. a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells, will present initial results from a [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.681754845